5.2 Electrical Stimulation, Ultrasound, and Topical Adjuncts
Key Takeaways
- Adjunctive therapies are selected only after wound etiology, wound bed status, contraindications, and facility policy are addressed.
- Electrical stimulation and ultrasound items test indication, scope, implanted-device and malignancy cautions, sensation, patient tolerance, and reassessment.
- Topical adjuncts do not replace cleansing, moisture balance, debridement, pressure control, or infection workup; antimicrobials need a stop point.
- The trap is using an adjunct as a universal rescue for a stalled wound without first asking why healing stalled.
Adjunctive therapy selection
The Treatment domain (25%) includes adjunctive therapies, but the WCC exam never rewards a device-first mindset. A therapy is justified only if it is matched to the right wound problem, used within scope, documented, and reevaluated. The WCC credential is for licensed practitioners working under state practice acts and employer guidelines, so scope is embedded in every adjunct question.
Adjuncts surface when a wound is stalled despite sound wound bed preparation, often defined on the exam as failure to reduce surface area by roughly 40 to 50% over four weeks of appropriate care. Before reaching for a device, screen the modifiable barriers: perfusion, pressure/shear, infection or bioburden, edema, nutrition, glycemic control (an A1c above 7% and persistent hyperglycemia impair healing), medication effects (steroids, chemotherapy), and adherence.
Category map with safety screens
| Adjunct category | Exam purpose | Safety and scope screen |
|---|---|---|
| Electrical stimulation (e-stim) | Best evidence-supported adjunct for chronic stage 3/4 pressure injuries and select diabetic/venous ulcers | Screen pacemaker/implanted electronic devices, electrodes near the heart or over malignancy, impaired sensation, pregnancy site, and policy clearance |
| Therapeutic/low-frequency ultrasound | Selected tissue-healing or debridement protocols | Confirm order, trained operator, avoid over malignancy, DVT, ischemic tissue, or active osteomyelitis |
| Topical antimicrobial (silver, iodine, PHMB, honey) | Lowers local bioburden when local infection suspected | Reassess at 2 weeks; prolonged use can be cytotoxic and mask failure to treat the cause |
| Collagen / matrix dressing | Supports a moist, clean bed | Do not place over unmanaged necrosis or heavy uncontrolled exudate |
| Cellular and/or tissue-based product (CTP, skin substitute) | Selected nonhealing diabetic/venous ulcers | Verify wound bed readiness, eligibility/payer rules, and documentation of failed standard care |
Applied WCC scenario
A venous leg ulcer has been dressed with the same foam for six weeks, measurements are unchanged, and edema is uncontrolled. The best next step is not a costly matrix product. Reassess compression appropriateness and arterial status, exudate, infection signs, nutrition, and adherence, then correct the cause before adding an adjunct. Adding a skin substitute over an edematous, noncompressed limb wastes resources and still will not heal.
Electrical stimulation and ultrasound stems hide contraindication clues. An implanted cardiac device, electrodes over the heart, malignancy in the field, impaired protective sensation, active DVT, untreated osteomyelitis, or inability to report discomfort can flip the answer toward pause-and-verify. When safety data are incomplete, choose the option that checks policy and obtains clearance rather than the most aggressive device option.
Topical adjuncts carry their own trap. A silver or iodine dressing helps when local infection or critical colonization is present, but indefinite routine use damages healthy fibroblasts and hides an untreated cause. Reassess antimicrobials at about two weeks. Growth factors and CTPs fail on a dry, necrotic, ischemic, or still-pressured wound.
Documentation
Link the adjunct to a measurable goal: why chosen, baseline wound size and tissue, the contraindication review, education, tolerance, product/device used, settings, and the planned reassessment point. The exam favors objective reassessment because Re-Evaluation (16%) is its own domain.
Exam traps
- The most advanced-sounding answer is not automatically correct; new odor, fever, rising pain, ischemic signs, or undermining points to infection or vascular workup and referral, not an added device.
- Forgetting the implanted-device and malignancy screens for e-stim and ultrasound.
- Treating advanced therapy as a substitute for diagnosis, source control, or prevention.
How electrical stimulation and ultrasound actually work
Electrical stimulation is the single adjunct with the strongest evidence base in chronic wound guidelines, which is why it appears more than its share on the exam. It applies a low-level current through electrodes to mimic the skin's natural bioelectric "current of injury," attracting reparative cells (galvanotaxis), enhancing perfusion, and supporting epithelial migration. Common waveforms include high-volt pulsed current.
The treatment area, electrode placement, polarity, and number of sessions are provider-ordered and operator-applied, so a WCC scenario rarely asks you to set parameters; it asks whether the patient is a safe candidate and whether the wound is stalled despite good basic care.
Therapeutic ultrasound delivers acoustic energy that produces thermal or nonthermal (cavitation, microstreaming) effects to stimulate tissue repair, while low-frequency contact ultrasound can also assist debridement. Avoid ultrasound over malignancy, active deep vein thrombosis, ischemic tissue, untreated osteomyelitis, the gravid uterus, and near electronic implants. As with e-stim, when the stem omits clearance for one of these conditions, the safest answer pauses to verify.
Cellular and tissue-based products and matrix dressings
Cellular and/or tissue-based products (skin substitutes) and collagen matrices are high-cost adjuncts reserved for diabetic or venous ulcers that have failed roughly four weeks of optimized standard care, including offloading or compression. The wound bed must be clean, adequately perfused, and free of clinical infection before placement, and documentation of failed standard care is usually required for payer approval. Placing a matrix on a necrotic, ischemic, infected, or still-pressured wound wastes the product and delays healing, which is the recurring exam lesson: optimize the basics and confirm readiness before escalating.
Always tie the adjunct to a measurable goal and a defined reassessment interval so the Re-Evaluation domain is satisfied.
A stalled venous ulcer has persistent edema and inconsistent compression use. What is the best WCC action before adding an expensive topical matrix product?
Which finding is the strongest reason to pause before starting electrical stimulation therapy?
What is the key exam trap with topical antimicrobial adjuncts?